Research ArticleFEATURED BASIC SCIENCE ARTICLE
Development of a 213Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates
Aidan A. Bender, Emily K. Kirkeby, Donna J. Cross, Satoshi Minoshima, Andrew G. Roberts and Tara E. Mastren
Journal of Nuclear Medicine September 2024, 65 (9) 1467-1472; DOI: https://doi.org/10.2967/jnumed.124.267482
Aidan A. Bender
1Nuclear Engineering Program, University of Utah, Salt Lake City, Utah;
Emily K. Kirkeby
2Department of Chemistry, University of Utah, Salt Lake City, Utah; and
Donna J. Cross
3Department of Radiology, University of Utah, School of Medicine, Salt Lake City, Utah
Satoshi Minoshima
3Department of Radiology, University of Utah, School of Medicine, Salt Lake City, Utah
Andrew G. Roberts
2Department of Chemistry, University of Utah, Salt Lake City, Utah; and
Tara E. Mastren
1Nuclear Engineering Program, University of Utah, Salt Lake City, Utah;

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 9
September 1, 2024
Development of a 213Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates
Aidan A. Bender, Emily K. Kirkeby, Donna J. Cross, Satoshi Minoshima, Andrew G. Roberts, Tara E. Mastren
Journal of Nuclear Medicine Sep 2024, 65 (9) 1467-1472; DOI: 10.2967/jnumed.124.267482
Jump to section
Related Articles
Cited By...
- No citing articles found.